香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年8月20日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 江苏恒瑞医药股份有限公司 2025 年半年度报告 公司代码：600276 ...

Social Security & Healthcare - The document discusses the option of only paying for resident medical insurance instead of social security [1] - It highlights a shift towards mandatory social security contributions [3] - The author expresses concern for self-employed individuals who voluntarily pay for social security [3] - The author argues that most young people who pay for medical insurance rarely use it [3] Personal Finance Perspective - The author criticizes the perceived "word game" where individuals still pay out-of-pocket even with medical insurance [3]

Social Security & Healthcare Analysis - The analysis suggests that many young individuals who pay for medical insurance may not actually utilize it, implying a potential inefficiency in the system [1] - The analysis points out that the "self-paid" portion of medical expenses often comes from individual accounts rather than pooled funds, despite the perception of insurance coverage [2][3] - The analysis suggests that resident medical insurance offers a cost-effective option for major illnesses, especially hospitalization, despite procedural hurdles [5][6] - The analysis views commercial insurance as a gamble against insurance companies, advising against it for individuals with sufficient assets (e g, 1 million in emergency cash) due to potentially unfavorable terms [6] Pension & Public Fund Insights - The analysis highlights the significant disparity in pension benefits based on employment type (e g, civil servants, state-owned enterprises, private companies, freelancers), with civil servants receiving substantially higher pensions [7] - The analysis implies that individuals in less advantageous positions within the pension system should minimize contributions as a form of resistance [8] - The analysis suggests that housing provident fund (公积金) is a tangible benefit that should be considered as part of one's income [9] - The analysis notes a decreasing trend in companies willing to take risks to help employees avoid taxes, as the risks outweigh the benefits [9] - The analysis suggests that the value of residency permits (落户) and housing purchase qualifications (房票) is diminishing, making continuous social security contributions for these purposes less worthwhile [9]

Group 1 - The core viewpoint of the articles highlights the benefits of the "Shenzhen Huimin Insurance" program, which allows residents to access advanced cancer treatment drugs from Hong Kong and Macau without the need for cross-border travel, significantly reducing their financial burden [1][2] - The program covers specific cancer treatment drugs, such as "Injection Rubrictin," which has been utilized by patients like Mr. Li and Ms. Zhou, leading to substantial reimbursements after medical expenses [1] - The total medical expenses incurred by Mr. Li amounted to 255,800 yuan, with the insurance covering 72,000 yuan after deducting the deductible, while Ms. Zhou's expenses were 129,500 yuan, with the insurance covering 18,600 yuan [1] Group 2 - The "Shenzhen Huimin Insurance" program for 2025 will see improvements, including a reduction in the deductible from 35,000 yuan to 31,000 yuan, and a further reduction to 30,000 yuan for those who have been insured for over two years, thus lowering the claims threshold [2] - The coverage will expand to include 17 types of medical products from Hong Kong and Macau, with an annual maximum reimbursement limit of 500,000 yuan, enhancing access to quality medical resources for residents [2] - The enrollment deadline for the 2025 "Shenzhen Huimin Insurance" program is set for June 30, and it is open to individuals who are normally enrolled and pay Shenzhen medical insurance, as well as Shenzhen residents with medical insurance from other locations [2]

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | 首届全球医美科技大会 参会需付费，价格：1200元/人。 名额有限，请尽早报名～ # 报名方法 请复制以下链接至IE浏览器 或 点击文末 " 阅读原文 "报名（会有工作人员联系） https://docs.qq.com/form/page/DUFpkTmZiSHVad0JJ 或者 扫描下方二维码报名 | 主持人:刘 贞 中国医学装备协会应用评价分会秘书长 | | --- | | 09:00-09:20 领导致辞 | | 嘉宾:蔡 葵 中国医学装备协会应用评价分会会长 | | 09:20-09:50《医院新产品准入流程》 | | 嘉宾:郑蕴欣 上海市第六人民医院临港院区副院长 | | 09:50-10:20 《高质量发展下创新医疗器械在医疗机构中的准入与评估》 | | 嘉宾:张璐璐 首都医科大学附属北京友谊医院医学工程处 | | 10:20-10:50《医院物价提单流程要求》 | | 嘉宾:赖雪蕾 北京市海淀医院、北京大学海淀区医学装备科主任 | | 10:50-11:00 茶歇 | | 11:00-11:30《VBP政策介 ...

Core Viewpoint - The article highlights the challenges faced by patients with myasthenia gravis, a rare autoimmune disease, including misdiagnosis, treatment difficulties, and the need for better healthcare support and awareness [1][4][11]. Group 1: Patient Challenges - Patients with myasthenia gravis often experience symptoms such as sudden weakness, drooping eyelids, and difficulty swallowing, leading to misdiagnosis as psychological issues or other conditions [3][4]. - The prevalence of myasthenia gravis is approximately 7.4 per million people, translating to around 650,000 patients in China due to the large population [4][7]. - Many patients report being misdiagnosed for years, which delays appropriate treatment and exacerbates their condition [3][4]. Group 2: Treatment and Healthcare Support - Current treatments for myasthenia gravis include cholinesterase inhibitors, corticosteroids, and immunosuppressants, but many essential medications are not covered by insurance, leading to high out-of-pocket costs [7][8]. - The new national medical insurance drug list, effective January 1, 2024, includes two medications for myasthenia gravis, but patients still face significant financial burdens for ongoing and crisis treatments [7][8]. - Experts suggest that myasthenia gravis should be included in outpatient chronic disease categories to improve reimbursement rates and access to necessary medications [8][9]. Group 3: Psychological and Social Aspects - The psychological impact of myasthenia gravis is significant, with many patients facing discrimination and social stigma due to visible symptoms like drooping eyelids [11]. - A study indicated that 17.1% of surveyed patients experienced discrimination affecting their work and study opportunities, highlighting the need for greater societal awareness and support [11]. - Mental health support is emphasized as a crucial component of treatment, alongside physical health interventions [11].